Concepedia

Author

Xavier Montalbán

Vall d'Hebron Hospital UniversitariORCID

Also Known As

Alex Rovira, Biberacher, V., BiomarkerMS Study Group, D. Miller, D. Seliak, David H Miller, David Miller, Fafard, Lori, Fernando Sanchez Lopez, Hartung, H-P

1.4K

Publications

87.4K

Citations

125

H-Index

232

Concepts

All Affiliations

Vall d'Hebron Hospital UniversitariUniversitat Autònoma de BarcelonaVall d'Hebron Institut de RecercaCentre d'Esclerosi Múltiple de CatalunyaUniversity Hospital of Basel
XM

About

Xavier Montalbán is an author at Vall d'Hebron Hospital Universitari specializing in medicine, multiple sclerosis, and neurology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

61

171

28.2K

2

Public Health

24

30

4.8K

3

Health Sciences

15

17

12.6K

4

Engineering

3

3

93

5

Natural Sciences

1

1

12

Xavier Montalbán

×

500

Publications

62.1K

Citations

108

H-Index

YearCitations

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

Chris H. Polman, Stephen C. Reingold, Brenda Banwell,

Annals of Neurology

2011

9.7K

Defining the clinical course of multiple sclerosis

Fred Lublin, Stephen C. Reingold, Jeffrey A. Cohen,

Neurology

2014

3K

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

Jeffrey A. Cohen, Frederik Barkhof, Hans‐Peter Hartung,

New England Journal of Medicine

2010

2.2K

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

Stephen L. Hauser, Amit Bar‐Or, Gavin Giovannoni,

New England Journal of Medicine

2016

1.9K

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

Xavier Montalbán, Stephen L. Hauser, Ludwig Kappos,

New England Journal of Medicine

2016

1.8K

Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility

Nikolaos A. Patsopoulos, Sergio E. Baranzini, Adam Santaniello,

Science

2019

1.3K

Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis

Ludwig Kappos, Jack P. Antel, Giancarlo Comi,

New England Journal of Medicine

2006

1.1K

Multiple Sclerosis Severity Score

Richard Roxburgh, Shaun R. Seaman, Thomas Masterman,

Neurology

2005

945

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree,

The Lancet

2018

896

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes

Ludwig Kappos, C. H. Polman, Mark S. Freedman,

Neurology

2006

672

Page 1